Clinical trials: Steroid Refractory GVHD
Graft-versus-Host Disease
Study on the Safety and Effectiveness of VELCADE® in the Treatment of Graft-Versus-Host Disease
The purpose of this research study is to test the safety and effectiveness of VELCADE® in the treatment of acute graft-versus-host disease (GVHD) that has not responded to steroids or has worsened when the steroid dose was…
- Trial name
- NCT00408928
- Testing
- Bortezomib
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Graft Versus Host Disease
In-vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus
In this study the investigators are proposing to treat patients with steroid-refractory Graft-versus-host Disease (GVHD) stabilization using IL-2 and azacitidine
- Trial name
- T-REG (NCT01453140)
- Testing
- Cyclophosphamide and Sirolimus, Low dose IL-2 with Cytoxan + Sirolimus, Low dose IL-2, low dose Vidaza, cyclophosphamide & Sirolimus
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Hackensack Meridian Health
Inflammatory Diseases
Study of Efavaleukin Alfa in Healthy Chinese, Japanese, and Caucasian Participants
The primary objective of this study is to evaluate the pharmacokinetics (PK) of efavaleukin alfa after single subcutaneous (SC) administration in healthy Chinese, Japanese, and Caucasian participants.
- Trial name
- NCT04987333
- Testing
- Efavaleukin alfa
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Amgen
Chronic Graft Versus Host Disease
Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease
This pilot clinical trial studies how well vismodegib works in treating patients with chronic graft-versus-host disease that did not respond to previous steroid treatment.
- Trial name
- NCT02337517
- Testing
- Laboratory Biomarker Analysis, Vismodegib
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
Acute Graft Versus Host Disease, Steroid Refractory Graft Versus Host Disease
Novel BET Inhibitor PLX51107 for Steroid-Refractory Acute GVHD
This phase Ib/II trial studies the side effects of PLX51107 in treating steroid-refractory acute graft versus host disease (GVHD).
- Trial name
- NCT04910152
- Testing
- BRD4 Inhibitor PLX51107
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Hannah Choe, MD
Chronic Graft Versus Host Disease cGVHD
Safety and Efficacy of Efavaleukin Alfa in Subjects With Steroid Refractory Chronic Graft Versus Host Disease
Phase 1b: To evaluate the safety and tolerability of multiple ascending doses of efavaleukin alfa in subjects with steroid refractory chronic graft versus host disease (cGVHD).
- Trial name
- NCT03422627
- Testing
- Efavaleukin Alfa
- Where
- 14 sites in United States, Belgium and 2 more
- Volunteers
- 32 people
- Sponsor
- Amgen
Graft-versus-host-disease, GVHD
A Proof of Concept Pilot Trial of Alpha-1-Antitrypsin for Pre-Emption Of Steroid-Refractory Acute GVHD
Bone marrow transplant (BMT) patients can develop graft-versus-host disease (GVHD), a serious and potentially fatal complication.
- Trial name
- NCT03459040
- Testing
- Alpha 1-Antitrypsin
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- John Levine
Chronic Graft Versus Host Disease
Abatacept to Treat Steroid Refractory Chronic Graft Versus Host Disease (cGVHD)
The participant is invited to take part in this study because they have chronic Graft versus Host Disease (cGVHD) that is not responding to standard treatment with steroids.
- Trial name
- NCT01954979
- Testing
- Abatacept
- Where
- 2 sites in United States
- Volunteers
- 56 people
- Sponsor
- Beth Israel Deaconess Medical Center
Graft-versus-host Disease (GVHD)
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)
The purpose of this study was to assess the efficacy of ruxolitinib in combination with corticosteroids in subjects with Grades II to IV steroid-refractory acute graft-versus-host disease (GVHD).
- Trial name
- NCT02953678
- Testing
- Ruxolitinib, Prednisone or methylprednisolone
- Where
- 38 sites in United States
- Volunteers
- 71 people
- Sponsor
- Incyte Corporation
Graft Versus Host Disease, Steroid Refractory GVHD
Infliximab and Basiliximab for Treatment of Steroid Refractory Acute Graft Versus Host Disease
Acute Graft Versus Host Disease (GVHD) is a serious medical condition that is a common development after Bone Marrow Transplant (BMT).
- Conditions
- Graft Versus Host Disease, Steroid Refractory GVHD, Acute GVH Disease
- Trial name
- NCT01485055
- Testing
- Infliximab and Basiliximab
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- Nationwide Children's Hospital
Chronic Graft Versus Host Disease
Extracorporeal Photopheresis and Low Dose Aldesleukin in Treating Patients With Steroid Refractory Chronic Graft-Versus-Host Disease
This phase II trial studies efficacy of extracorporeal photopheresis and low dose aldesleukin (interleukin-2) in treating patients with chronic graft-versus-host disease (cGVHD) that does not respond to upfront treatment with…
- Trial name
- NCT03007238
- Testing
- Aldesleukin, Extracorporeal Photopheresis, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- City of Hope Medical Center
Chronic Graft Versus Host Disease
Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD)
To evaluate the safety and efficacy of ibrutinib in combination with prednisone in subjects with newly diagnosed moderate to severe cGVHD.
- Trial name
- iNTEGRATE (NCT02959944)
- Testing
- ibrutinib, Prednisone
- Where
- 102 sites in United States, Australia and 13 more
- Volunteers
- 193 people
- Sponsor
- Pharmacyclics LLC.
Graft Versus Host Disease
Efalizumab in Treating Patients With Graft-Versus-Host Disease of the Skin That Did Not Respond to Previous Steroids
RATIONALE: Efalizumab may be an effective treatment for graft-versus-host disease of the skin caused by a donor stem cell transplant.
- Trial name
- NRR (NCT00489216)
- Testing
- efalizumab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Chronic Graft-versus-host-disease
A Study of Itacitinib for the Treatment of Chronic Graft Versus Host Disease (cGVHD)
This study is being done in patients who have been receiving corticosteroids or other immunosuppressive therapies for the treatment of cGVHD for at least 6 months.
- Trial name
- NCT04200365
- Testing
- Itacitinib
- Where
- 5 sites in United States
- Volunteers
- 15 people
- Sponsor
- SCRI Development Innovations, LLC
Graft vs Host Disease
A Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Steroid Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD)
The purpose of this study is to evaluate efficacy of ibrutinib in Japanese participants with steroid dependent/refractory chronic graft versus host disease (cGVHD) by measuring overall cGVHD response (complete response [CR] and…
- Trial name
- NCT03474679
- Testing
- Ibrutinib
- Where
- 15 sites in Japan
- Volunteers
- 19 people
- Sponsor
- Janssen Pharmaceutical K.K.
Graft vs Host Disease
A Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Chronic Graft Versus Host Disease
This study was been conducted to evaluate the safety, tolerability, and activity of belumosudil (formerly known as KD025) in adult participants with chronic graft versus host disease (cGVHD).
- Trial name
- NCT02841995
- Testing
- Belumosudil (KD025)
- Where
- 7 sites in United States
- Volunteers
- 54 people
- Sponsor
- Kadmon, a Sanofi Company